医学
药物重新定位
重新调整用途
肺癌
药品
化疗
癌症
肿瘤科
抗药性
药效学
癌
内科学
药理学
药代动力学
生物
生态学
微生物学
作者
George Doumat,Darine Daher,Morgan Bou Zerdan,Nasri Nasra,Hisham F. Bahmad,Monica Recine,Robert Poppiti
标识
DOI:10.3390/curroncol30010055
摘要
Lung cancer is the second most common cancer and the leading cause of cancer-related deaths in 2022. The majority (80%) of lung cancer cases belong to the non-small cell lung carcinoma (NSCLC) subtype. Despite the increased screening efforts, the median five-year survival of metastatic NSCLC remains low at approximately 3%. Common treatment approaches for NSCLC include surgery, multimodal chemotherapy, and concurrent radio and chemotherapy. NSCLC exhibits high rates of resistance to treatment, driven by its heterogeneity and the plasticity of cancer stem cells (CSCs). Drug repurposing offers a faster and cheaper way to develop new antineoplastic purposes for existing drugs, to help overcome therapy resistance. The decrease in time and funds needed stems from the availability of the pharmacokinetic and pharmacodynamic profiles of the Food and Drug Administration (FDA)-approved drugs to be repurposed. This review provides a synopsis of the drug-repurposing approaches and mechanisms of action of potential candidate drugs used in treating NSCLC, including but not limited to antihypertensives, anti-hyperlipidemics, anti-inflammatory drugs, anti-diabetics, and anti-microbials.
科研通智能强力驱动
Strongly Powered by AbleSci AI